2025-520716-34-00已完成4 期
Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions
Bluepharma Industria Farmaceutica S.A.1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2025年3月7日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Affairs Department
Scientific
Bluepharma Industria Farmaceutica S.A.
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.2023-508339-29-00Bluepharma Industria Farmaceutica S.A.12
已完成
1 期
A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy ParticipantsHealthy ParticipantsNCT06555081Incyte Corporation168
进行中（未招募）
1 期
Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEAT Trialpolycythemia vera, essential thrombocythemiaCTIS2024-515619-23-00niversitaetsklinikum Aachen AöR223
进行中（未招募）
1 期
RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT TrialMyeloproliferative Neoplasms (MPN): high-risk Polycythemia Vera (PV) and high-risk Essential Thrombocythemia (ET)EUCTR2013-002132-25-DEniversity Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty380
已完成
3 期
Study of efficacy and safety of ruxolitinib vs. best available therapy (BAT) in patients with corticosteroid refractory chronic graft versus host diseasejRCT2080223697Novartis Pharma. K.K.324